We are live on
!
Find out more
TC
Tavio Capital Portfolio holdings
AUM
$75.4M
1-Year Est. Return
27.99%
This Fund
S&P 500
This Quarter
Est. Return
+16.4%
1 Year Est. Return
+27.99%
3 Year Est. Return
+81.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$256M
AUM Growth
-$38.9M
(-13%)
Cap. Flow
-$67.3M
Cap. Flow
% of AUM
-26.24%
Top 10 Holdings %
Top 10 Hldgs %
83.87%
Holding
22
New
5
Increased
5
Reduced
6
Closed
4
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
+$29.2M |
| 2 |
Molina Healthcare
MOH
|
+$6.27M |
| 3 |
Universal Health Services
UHS
|
+$5.31M |
| 4 |
Labcorp
LH
|
+$5.19M |
| 5 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$5.16M |
Top Sells
| 1 |
Quest Diagnostics
DGX
|
+$39.9M |
| 2 |
HCA Healthcare
HCA
|
+$20.2M |
| 3 |
Boston Scientific
BSX
|
+$14.3M |
| 4 |
Cencora
COR
|
+$13.2M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Elevance Health
ELV
$80.9B
| $49.4M | 19.28% |
180,374
+15,842
| +10% | +$4.11M |
|
|
2
Zimmer Biomet
ZBH
$17.6B
| $31.4M | 12.24% |
+245,846
| New | +$29.2M |
|
3
CVS Health
CVS
$137B
| $24.8M | 9.68% |
315,380
-114,620
| -27% | -$8.19M |
|
|
4
Molina Healthcare
MOH
$11.7B
| $22.5M | 8.78% |
151,368
+49,130
| +48% | +$6.27M |
|
5
Centene
CNC
$32.8B
| $22.1M | 8.63% |
305,680
-31,512
| -9% | -$2.19M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $16.3M | 6.35% |
182,027
+56,619
| +45% | +$5M |
|
|
7
Cencora
COR
$59.9B
| $16.1M | 6.28% |
174,578
-152,511
| -47% | -$13.2M |
|
8
Humana
HUM
$48B
| $11.5M | 4.5% |
34,062
-19,170
| -36% | -$6.23M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
| $11.1M | 4.33% |
79,856
-85,077
| -52% | -$10.7M |
|
10
Heron Therapeutics
HRTX
$89.1M
| $9.74M | 3.8% |
307,737
+31,008
| +11% | +$1.15M |
|
11
Travere Therapeutics
TVTX
$5.27B
| $8.44M | 3.29% |
293,923
| – | – |
|
|
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
| $5.96M | 2.32% |
120,160
+40,000
| +50% | +$2.04M |
|
|
13
Universal Health Services
UHS
$9.15B
| $5.53M | 2.16% |
+43,279
| New | +$5.31M |
|
|
PDCO
14
DELISTED
Patterson Companies, Inc.
PDCO
| $5.32M | 2.07% |
+217,581
| New | +$5.16M |
|
15
Medpace
MEDP
$15.4B
| $5.19M | 2.03% |
+86,670
| New | +$4.74M |
|
|
16
Labcorp
LH
$23.2B
| $5.09M | 1.99% |
+34,120
| New | +$5.19M |
|
|
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
| $4.87M | 1.9% |
402,955
| – | – |
|
|
18
Boston Scientific
BSX
$65.4B
| $950K | 0.37% |
24,671
-410,659
| -94% | -$14.3M |
|
|
19
Quest Diagnostics
DGX
$23.3B
| – | – |
-362,612
| Closed | -$39.9M |
|
|
20
HCA Healthcare
HCA
$82.3B
| – | – |
-197,318
| Closed | -$20.2M |
|
21
UnitedHealth
UNH
$387B
| – | – |
-42,435
| Closed | -$10.4M |
|
|
AET
22
DELISTED
Aetna Inc
AET
| – | – |
-55,346
| Closed | -$10.2M |
|
Similar funds
PC
EGPO
AIS
MCMT
NBG
FC
SCM
MVM
Tavio Capital's Q3 2018 Portfolio in Review
As of Q3 2018, Tavio Capital held 22 positions worth $256M, down 13% from $295M the previous quarter. Its ten largest holdings account for 84% of the portfolio.
Tavio Capital withdrew a net $67.3M in Q3 2018, closing 4 positions and reducing 6 holdings. Its most notable exit was Quest Diagnostics, an estimated $39.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Financials.
Against the trend, Tavio Capital opened a new position in Zimmer Biomet worth $31.4M.
- Tavio Capital's largest Q3 2018 buy was Zimmer Biomet: 245,846 shares worth $31.4M.
- Tavio Capital added most to Molina Healthcare in Q3 2018, an estimated $6.27M increase.
- Tavio Capital's biggest Q3 2018 reduction was Boston Scientific, cutting an estimated $14.3M.
- Tavio Capital fully exited Quest Diagnostics in Q3 2018, selling an estimated $39.9M.
- Tavio Capital's ten largest holdings make up 84% of its $256M portfolio in Q3 2018.
- Tavio Capital opened 5 new positions and closed 4 in Q3 2018.
- Tavio Capital's portfolio value fell 13% quarter-over-quarter to $256M.
Based on Tavio Capital's 13F filing for Q3 2018, filed 13 Nov 2018.